Signal transduction pathway activity compensates dopamine D2/D3 receptor density changes in Parkinson's disease: a preliminary comparative human brain receptor autoradiography study with [3H]raclopride and [35S]GTPγS

[1]  L. Minuzzi,et al.  Agonist binding fraction of dopamine D2/3 receptors in rat brain: A quantitative autoradiographic study , 2010, Neurochemistry International.

[2]  C. Bouras,et al.  Neuropathology of Lewy body disorders , 2009, Brain Research Bulletin.

[3]  M Schulzer,et al.  PET demonstrates reduced dopamine transporter expression in PD with dyskinesias , 2009, Neurology.

[4]  Vesna Sossi,et al.  Dopamine transporter relation to levodopa‐derived synaptic dopamine in a rat model of Parkinson’s: an in vivo imaging study , 2009, Journal of neurochemistry.

[5]  S. Meikle,et al.  Challenges in molecular imaging of Parkinson’s disease: A brief overview , 2009, Brain Research Bulletin.

[6]  Jessica A. Grahn,et al.  The cognitive functions of the caudate nucleus , 2008, Progress in Neurobiology.

[7]  M. Horne,et al.  Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. , 2008, Brain : a journal of neurology.

[8]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[9]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[10]  Christer Halldin,et al.  Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride , 2006, Synapse.

[11]  B. Gulyás,et al.  Autoradiographic mapping of dopamine-D 2 ⁄D 3 receptor stimulated ( 35 S)GTPcS binding in the human brain , 2005 .

[12]  Philip Seeman,et al.  Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Owen.  Cognitive Dysfunction in Parkinson’s Disease: The Role of Frontostriatal Circuitry , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[14]  A. Benabid,et al.  Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. , 2004, Archives of neurology.

[15]  B. Thanvi,et al.  Long term motor complications of levodopa: clinical features, mechanisms, and management strategies , 2004, Postgraduate Medical Journal.

[16]  D. Calne,et al.  Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. , 2004, Brain : a journal of neurology.

[17]  S. Munshi,et al.  Neuropsychiatric non-motor aspects of Parkinson’s disease , 2003, Postgraduate medical journal.

[18]  J. Eberling,et al.  Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. , 2003, Frontiers in bioscience : a journal and virtual library.

[19]  Hoau Yan Wang,et al.  Increased Dopamine Receptor Signaling and Dopamine Receptor-G Protein Coupling in Denervated Striatum , 2002, Journal of Pharmacology and Experimental Therapeutics.

[20]  P. Jenner,et al.  Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets , 2001, The European journal of neuroscience.

[21]  J. Labandeira-Garcia,et al.  Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum , 2001, Neuroscience.

[22]  G. Sedvall,et al.  Autoradiographic localization of 5‐HT2A receptors in the human brain using [3H]M100907 and [11C]M100907 , 2000, Synapse.

[23]  V Kaasinen,et al.  Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease , 2000, Neurology.

[24]  Xuechu Zhen,et al.  Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D2Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats , 2000, The Journal of Neuroscience.

[25]  J. Obeso,et al.  Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. , 1999, Clinical neuropharmacology.

[26]  G. Chiro,et al.  NMSP binding to dopamine and serotonin receptors in MPTP‐induced parkinsonism: relation to dopa therapy , 1999, Acta Neurologica Scandinavica.

[27]  Anders Björklund,et al.  Prospects for new restorative and neuroprotective treatments in Parkinson's disease , 1999, Nature.

[28]  Geoffrey A. Donnan,et al.  Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor , 1999, The Journal of Neuroscience.

[29]  E. Perry,et al.  Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine , 1999, Neuroscience.

[30]  G. Sedvall,et al.  Whole hemisphere autoradiography of the postmortem human brain. , 1998, Nuclear medicine and biology.

[31]  R. Roth,et al.  Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study , 1998, Brain Research.

[32]  W. Poewe,et al.  123I‐β‐CIT and 123I‐IBZM‐SPECT scanning in levodopa‐naive Parkinson's disease , 1998 .

[33]  T. McNeill,et al.  Lesion-induced axon sprouting in the deafferented striatum of adult rat , 1998, Neuroscience Letters.

[34]  M. Caron,et al.  Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. , 1997, Molecular pharmacology.

[35]  J. Féger.  Updating the functional model of the basal ganglia , 1997, Trends in Neurosciences.

[36]  K. Leenders,et al.  Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.

[37]  Lars Farde,et al.  Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907 , 1996, Psychopharmacology.

[38]  P. Bédard,et al.  Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates , 1996, Brain Research.

[39]  Ulla Ruotsalainen,et al.  Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride , 1995, Journal of the Neurological Sciences.

[40]  Y. Agid,et al.  Long‐Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat Brain , 1995, Journal of neurochemistry.

[41]  M. Piercey,et al.  Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[42]  Christer Halldin,et al.  Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.

[43]  J. Joyce,et al.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  B. Weiss,et al.  Irreversible blockade of D2 dopamine receptors by fluphenazine-N-mustard increases D2 dopamine receptor mRNA and proenkephalin mRNA and decreases D1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum , 1994, Neurochemistry International.

[45]  A. Antonini,et al.  [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.

[46]  R. Schwartzman,et al.  Changes in brain dopamine receptors in MPTP parkinsonian monkeys followingL-dopa treatment , 1993, Brain Research.

[47]  D. Jackson,et al.  Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. , 1993, Molecular pharmacology.

[48]  Robert M. Kessler,et al.  Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride , 1993, Brain Research.

[49]  J. Palacios,et al.  High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review. , 2012, Analytica chimica acta.

[50]  M. Sambrook,et al.  Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism , 1993, Brain Research.

[51]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[52]  J. Hsiao,et al.  In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis , 1990, Experimental Neurology.

[53]  G. E. Alexander,et al.  Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.

[54]  S. Boyce,et al.  Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis) , 1990, Brain Research.

[55]  Mohamed N. Hassan,et al.  Dopamine receptors in Parkinson's disease , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[56]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[57]  S. Fahn,et al.  Chronic levodopa or pergolide administration induces down‐regulation of dopamine receptors in denervated striatum , 1984, Neurology.

[58]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[59]  R. Bannister,et al.  Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease , 1979, Journal of the Neurological Sciences.

[60]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[61]  J. Fields,et al.  Neurotransmitter receptor alterations in Parkinson's disease. , 1977, Life sciences.

[62]  E. London,et al.  Estimation of D2-like Receptor Occupancy by Dopamine in the Putamen of Hemiparkinsonian Monkeys , 2008, Neuropsychopharmacology.

[63]  G. Corsini,et al.  Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration , 2005, Journal of Neural Transmission.

[64]  C. Marsden,et al.  Research report Dopamine D 3 :receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment , 1996 .

[65]  O. Hornykiewicz,et al.  Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. , 1993, Advances in neurology.

[66]  D. Brooks,et al.  In vivo and in vitro studies of the dopaminergic system in movement disorders. , 1992, Cerebrovascular and brain metabolism reviews.

[67]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.

[68]  J. Rinne,et al.  Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. , 1983, Journal of neural transmission. Supplementum.